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Contribution:  47 
A. What are the novel findings of this work? 48 
The rate of miscarriage after chorionic villous sampling (CVS) is highly 49 
dependent on the patient-specific background risk of miscarriage without CVS. 50 
Because the several factors that lead to CVS are also associated with 51 
spontaneous miscarriage, in women at low-risk of aneuploidies, CVS is 52 
associated with a significant increase in the miscarriage rate while, 53 
paradoxically, when the risk is high, the risk of miscarriage after CVS is 54 
reduced, presumably due to prenatal diagnosis and termination of major 55 
aneuploidies that would have otherwise resulted in spontaneous miscarriage. 56 
B. What are the clinical implications of this work? 57 
The true procedure-related risk of miscarriage from CVS can only be derived 58 
by examining women at low-risk of aneuploidies and in such women their risk 59 
of miscarriage increases by about three times after CVS. Although this is a 60 
substantial increase in relative terms, in pregnancies without prior risk factors 61 
the risk of miscarriage after CVS will still remain low and similar to or slightly 62 






Objective: To estimate the risk of miscarriage associated to chorionic villus sampling 65 
(CVS). 66 
Methods: This was a retrospective cohort study performed in eight fetal-medicine 67 
units in Spain, Belgium and Bulgaria. Two populations were included: first, all 68 
singleton pregnancies attending to their first-trimester assessment in Murcia, Spain, 69 
and second, all singleton pregnancies having a CVS following first-trimester 70 
assessment at any of the participating centers. We used propensity score matching 71 
analysis to estimate the association between CVS and miscarriage. We compared 72 
risks of miscarriage of CVS and non-CVS groups after propensity score matching 73 
(1:1 ratio). This procedure creates two comparable groups balancing the maternal 74 
and pregnancy characteristics that lead to CVS, in a similar way in which 75 
randomization operates in a randomized clinical trial.  76 
Results: The study population consisted of 22,250 participants in the non-CVS group 77 
and 3,613 in the CVS group. The incidence of miscarriage in the CVS group was 78 
2.1% (77/3,613), which was significantly higher than the 0.9% (207/22,250) in the 79 
non-CVS group (p <0.001). The propensity score algorithm matched 2,122 CVS 80 
cases with 2,122 non-CVS cases including 40 (1.9%) and 55 (2.6%) miscarriages in 81 
the CVS and non-CVS groups, respectively (OR 0.72 [95% CI 0.48 to 1.10]; p = 82 
0.146). However, we found a significant interaction between the CVS risk of 83 
miscarriage and the risk of aneuploidies, suggesting a different effect of the CVS for 84 
different baseline characteristics in such a way that, when the risk of aneuploidies is 85 





is high, the risk after CVS is paradoxically reduced (OR 0.47 [95% CI 0.28 to 0.76]), 87 
presumably due to prenatal diagnosis and termination of major aneuploidies that 88 
would have otherwise resulted in spontaneous miscarriage. 89 
Conclusions: The risk of miscarriage in women having a CVS is about 1% higher 90 
than in women without CVS, although this excess risk is not entirely due to the 91 
invasive procedure but to some extent the demographic and pregnancy 92 
characteristics of the patient undergoing CVS. After accounting for these risk factors 93 
and confining the analysis to low-risk pregnancies, CVS seems to increase the risk 94 
of miscarriage about three times above the patient’s background-risk. Although this 95 
is a substantial increase in relative terms, in pregnancies without risk factors, the risk 96 
of miscarriage after CVS will still remain low and similar to or slightly higher than that 97 
of the general population. For example, if her risk of aneuploidy is 1 in a 1,000 98 
(0.1%), her risk of miscarriage after CVS will increase to 0.3% (0.2% higher). 99 
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Chorionic villous sampling (CVS), which was first described in 19751 and introduced 105 
into widespread practice in the 1980’s, is a useful invasive test for early prenatal 106 
diagnosis of chromosomal and genetic abnormalities. The procedure related risk of 107 
miscarriage was not investigated in studies that randomized women into CVS vs. 108 
non-invasive testing groups. However, the risk was derived indirectly through first, 109 
randomized control trials (RCTs) comparing CVS with first or second trimester 110 
amniocentesis, and second, comparison of rates of miscarriage in groups with 111 
similar risk factors that had CVS with those that did not have invasive testing. The 112 
results of trials established that first, the risk of miscarriage following CVS was lower 113 
than that of early amniocentesis but similar to that of mid-trimester amniocentesis, 114 
and second, the risk of transabdominal and transcervical CVS was similar.2-7 115 
Consequently, since the only trial comparing mid-trimester amniocentesis to 116 
expectant management reported a 1% higher risk of miscarriage in the 117 
amniocentesis group,8 it was assumed that the risk of miscarriage from CVS was 118 
also about 1%. 119 
Another approach for estimating the procedure-related risk of miscarriage from 120 
CVS is to compare rates of miscarriage in groups that had CVS with those that did 121 
not have invasive testing. However, such an approach is likely to provide a bias 122 
against CVS because several of the factors that lead to CVS are also risk factors for 123 
miscarriage, i.e. increased maternal age, increased fetal nuchal translucency (NT), 124 
low serum pregnancy associated plasma protein-A (PAPP-A), and abnormal flow in 125 





carry out logistic regression analysis to identify predictors of miscarriage in women 127 
who did not have CVS and then apply the model to women who had CVS and 128 
compare the observed to the expected number of miscarriages in the latter group.13-129 
15 A second approach is to perform a propensity score (PS) analysis that creates two 130 
homogeneous groups suitable for comparisons.16 PS analysis has emerged as a 131 
robust methodology well suited to estimate causal effects from observational data 132 
while accounting for a greater number of confounder effects than classical 133 
multivariate analysis could adjust for.17,18 Studies utilizing these approaches 134 
reported that the procedure-related risk of miscarriage from CVS may be 135 
considerably lower than 1%.13-16 A recent meta-analysis included 7 studies 136 
comparing 13,011 women who had a CVS with 232,680 women who did not have 137 
the procedure and estimated the risk of miscarriage following CVS at 0.20% (95% 138 
CI, −0.13 to 0.52%).19 However, the results from the different studies were 139 
heterogeneous and the value of pooled estimates from meta-analyses in such cases 140 
is questionable.20   141 
The main objective of this multicenter study was to estimate the CVS-related risk 142 
of miscarriage after accounting for the effect of maternal and pregnancy 143 
characteristics which could have driven the decision around performing or not a 144 
CVS.  145 
 146 
METHODS 147 





This is a retrospective cohort study performed at eight fetal-medicine units in Spain 149 
(Hospital Clínico Universitario Virgen de la Arrixaca in Murcia, Hospital Clínico 150 
Universitario San Cecilio and Hospital Universtario Virgen de las Nieves in Granada, 151 
Hospiten de Tenerife in Tenerife and Hospital Universitario de Cruces in Bilbao), 152 
Belgium (Brugmann University Hospital in Brussels) and Bulgaria (Shterev Hospital 153 
and OSCAR Clinic in Sofia). In the participating centers women attended for a 154 
routine ultrasound examination at 11+0-13+6 weeks’ gestation. During this visit patient 155 
characteristics and medical history were recorded, ultrasound examination was 156 
carried out to assess viability, diagnose major defects and measure fetal crown-rump 157 
length (CRL) and fetal NT thickness and assess ductus venosus a-wave as positive 158 
or negative / reversed. Blood was also collected in the same visit (n = 651 [2.5%]) or 159 
1-2 weeks previously (n= 25,212 [97.5%]) for measurement of serum free β-human 160 
chorionic gonadotropin (β-hCG) and PAPP-A. Screening for trisomies 21, 18 and 13 161 
was carried out using The Fetal Medicine Foundation algorithm, which combines 162 
maternal age, fetal NT, ductus venosus flow and multiple of the median (MoM) 163 
values of free β-hCG and PAPP-A.21 The estimated risk for trisomies was then used 164 
to counsel women and in those choosing invasive testing CVS was performed by the 165 
same transabdominal technique by or under the supervision of a fetal medicine 166 
expert trained at King’s College Hospital, London, UK. Pregnancies were dated 167 
according to the fetal CRL at the time of screening if they were naturally conceived22 168 
and according to conception date if they were conceived by in-vitro fertilization. 169 
We recorded the following patient characteristics: maternal age, weight, height, 170 





conception (natural or assisted conception requiring the use of ovulation drugs or in-172 
vitro fertilization), cigarette smoking during pregnancy (yes or no) and parity (parous 173 
or nulliparous if no previous pregnancy at ≥ 24 weeks’ gestation), and medical history 174 
of diabetes mellitus and chronic hypertension (yes or no).  175 
Two populations were included in this study; first, all singleton pregnancies 176 
attending to their first-trimester assessment in Murcia (Spain) who did not have CVS, 177 
and second, all singleton pregnancies having a CVS following first-trimester 178 
assessment at any of the participating centers. In the control group there were 179 
21,873 (98.3%) pregnancies with a low-risk from the first-trimester combined test, 180 
345 (1.6%) with a high-risk and 32 (0.1%) who declined risk assessment. Indication 181 
for CVS was mainly increased risk for aneuploidies but also increased NT, history of 182 
genetic disease in the family, previous aneuploidy or even maternal request. The 183 
patients were examined between July 2007 and June 2018. The eligibility criteria 184 
were singleton pregnancy with a live fetus at 11+0 to 13+6 weeks without genetic 185 
anomalies or major fetal defects (such as acrania, holoprosencephaly, megacystis, 186 
exomphalos, congenital heart defects) diagnosed before or after birth. We excluded 187 
pregnancies resulting in termination for any reason, pregnancies without follow up 188 
and pregnancies having an amniocentesis later on in pregnancy. 189 
The primary outcome measure was miscarriage, defined as pregnancy loss 190 
occurring before 24 weeks’ gestation regardless of the interval between CVS and 191 
fetal demise. Results of the investigations and pregnancy outcome were recorded in 192 





from the relevant research ethics committee in each center in which the study was 194 
conducted.  195 
Statistical analyses  196 
Descriptive data were expressed as median and interquartile range (IQR) and in 197 
proportions (absolute and relative frequencies). Comparisons between treatment 198 
groups were performed by Mann-Whitney U-test or two-tailed χ2-test as appropriate. 199 
Analyses were run on a complete case basis, and the number of pregnancies 200 
included in each analysis were reported wherever necessary. Level of significance 201 
was set at 0.05. 202 
Because we noted important differences in baseline clinical characteristics 203 
between the CVS and the non-CVS groups, we performed a propensity score 204 
matching analysis to assess the effect of CVS in the risk of miscarriage adjusting for 205 
the confounding bias caused by this imbalance. Compared with classic multivariate 206 
adjustments, the PS permits finer adjustments for wider sets of covariates. The PS 207 
was defined as the conditional probability of having a CVS given the measured 208 
covariates in order to balance covariates in the two groups. To obtain the PS, we 209 
fitted a logistic regression model with CVS as dependent variable and then we 210 
modelled the conditional probability of having a CVS as a function of baseline and 211 
those clinical characteristics associated with having a CVS. We use the PS to match, 212 
without replacement, each complete CVS case with the non-CVS case with the 213 
closest PS in a 1:1 ratio, to optimise the precision of the estimate of association and 214 
limit bias. We also accepted cases only if the difference in PS between matched 215 





and the non-CVS cases as matched samples.23 We computed standardised 217 
differences for all variables included in the PS before and after matching to assess 218 
the effect of matching on the imbalance. We deemed a 10% standardized difference 219 
as the limit for a correct balance. After matching, we compared miscarriage rate 220 
between the CVS cases and those without CVS as matched groups. Finally, we 221 
calculated an odds ratio (OR) to quantify the association between CVS and 222 
miscarriage using a univariate logistic regression fitted by generalised estimating 223 
equations to account for matched data. 224 
The statistical software package R was used for data analyses. 24 The R package 225 
MatchIt25 was used for matching with PS. Analysis of matched cases was performed 226 
using the R package Geepack.26 227 
 228 
RESULTS  229 
Study population 230 
The study population consisted of 22,250 participants in the non-CVS group and 231 
3,613 in the CVS group (figure 1). Maternal and pregnancy characteristics are shown 232 
in Table 1. In the CVS group, compared to the non-CVS group, median maternal 233 
age, gestational age, fetal NT and serum free β-hCG MoM were significantly higher 234 
and maternal weight and PAPP-A MoM were lower, and the incidence of parous 235 
women, Black or South Asian racial origin, chronic hypertension and conception by 236 
assisted reproductive techniques and abnormal flow in the fetal ductus venosus was 237 
higher. The only parameter not significantly different was the frequency of pre-238 





The incidence of miscarriage in the CVS group was 2.1% (77/3,613), which was 240 
significantly higher than the 0.9% (207/22,250) in the non-CVS group (p <0.001).  241 
Procedure-related risk of miscarriage 242 
We calculated PS for each case in the study population based on their probability of 243 
having a CVS. Multivariable regression analysis demonstrated that significant 244 
predictors associated to having a CVS were increasing maternal age, decreasing 245 
maternal weight, assisted conception, chronic hypertension, increasing gestational 246 
age, high fetal NT, abnormal flow in the ductus venosus, high free β-hCG and low 247 
PAPP-A (Table S1).  248 
The PS algorithm matched 2,122 of our CVS cases with 2,122 non-CVS 249 
pregnancies, largely reducing the initial imbalance between women with and without 250 
CVS, with between-group standardized differences for all instances lower than the 251 
recommended 10% limit (figure 2, tables 1 and 2). The number of miscarriages was 252 
40 (1.9%) in the CVS group and 55 (2.6%) in the matched non-CVS group. PS 253 
analysis did not find any significant association between CVS and miscarriage (OR 254 
0.72 [95% CI 0.48 to 1.10]; p=0.146). We hypothesized that the most likely 255 
explanation for this paradoxical effect of CVS “decreasing” the risk of miscarriage 256 
was that many of the cases that would have resulted in spontaneous miscarriage 257 
had the pregnancy continued, were converted into elective pregnancy terminations 258 
following an abnormal genetic diagnosis. If this was true, this “protective” effect 259 
should be higher in cases at high-risk of having a genetic anomaly and lower in cases 260 





Therefore, we aimed to investigate whether the effect of having a CVS was the 262 
same in women at higher risk of aneuploidies as compared to those at lower risk. 263 
Thus, we investigated a possible interaction between the risk of aneuploidy and 264 
CVS. Since the risk factors associated to having a CVS are the same factors that 265 
increase the risk of aneuploidies, we divided our 4,244 matched cases in two equal 266 
groups by the median of the PS. The median PS was 0.402 (IQR 0.331-0.490) in the 267 
high-risk subgroup (n=2,122) and 0.131 (IQR 0.057, 0.197) in the low-risk subgroup 268 
(n=2,122). In the high-risk subgroup there were 1,062 cases having a CVS, including 269 
23 (2.2%) miscarriages and 1,060 non-CVS cases, including 49 (4.6%) miscarriages 270 
(OR 0.47 [95% CI 0.28 to 0.76]); in contrast, in the low-risk subgroup we found 17 271 
(1.6%) miscarriages in the CVS (n = 1,060) group compared to 6 (0.6%) 272 
miscarriages in the non-CVS (n= 1,062) group (OR 2.87 [95% CI 1.13 to 7.30]. Both 273 
effects were statistically different (p value of the interaction = 0.0003) (figure 3). 274 
These results suggest that there is something which makes the CVS behave 275 
differently when the risk of aneuploidies is high compared to when it is low. Thus, 276 
using the PS as a proxy of the risk of aneuploidies, for a patient with a 10% 277 
probability of aneuploidy based on her pregnancy characteristics, the risk of 278 
miscarriage after the procedure is still very high but halved to about 5%, suggesting 279 
that in such case CVS is highly “protective” of miscarriage. However, for a patient 280 
with a low probability of aneuploidy, her risk of miscarriage will increase. For 281 
example, if her risk of aneuploidy is 1 in a 1,000 (0.1%), her risk of miscarriage after 282 





500 CVSs to cause a miscarriage. Further analysis on this interaction is provided in 284 
Appendix 1. 285 
 286 
DISCUSSION 287 
Principal findings 288 
In this study we found that: first, following a first trimester scan demonstrating a 289 
structurally normal fetus, the risk of subsequent miscarriage for the general 290 
population is about 1%; second, in women having CVS the risk of miscarriage is 291 
about 1% higher than in women without CVS although this excess risk is not entirely 292 
due to the invasive procedure but to some extent the demographic and pregnancy 293 
characteristics of the patient undergoing CVS; and third, the actual procedure-294 
related risk of the CVS may only become apparent in patients at low risk of 295 
aneuploidies and, in these cases, the risk of miscarriage after CVS increases by 296 
about three times.  297 
We have demonstrated that, although in women at high-risk of aneuploidies CVS 298 
appears to be “protective” against miscarriage, the most likely explanation for this 299 
observation is that CVS leads to the diagnosis of major aneuploidies followed by 300 
elective pregnancy termination in cases that would have otherwise resulted in 301 
spontaneous miscarriage. In the CVS group we excluded 22.2% (1,135/5,112) of 302 
cases because of termination of pregnancy or fetal defects, compared to only 4.2% 303 
(1,070/25,519) in the non-CVS group (figure 1). Had these cases been included and 304 
the pregnancy had continued, many would have resulted in miscarriage and then the 305 





the non-CVS group. To try to avoid this selection bias, we studied separately the 307 
effect of the CVS in cases with a low probability of having a CVS and in those with 308 
a higher probability. Contrary to what happens in high-risk cases, in women at low 309 
risk of aneuploidies, the procedure significantly increases this risk by about three 310 
times.  311 
Comparison with findings of previous studies 312 
Our results offer an explanation for the contradictory findings of previous studies that 313 
showed that CVS did not significantly modify the risk of miscarriage, and a meta-314 
analysis that reported a non-significant “protective” effect of CVS against 315 
miscarriage17.  316 
First, one large study examined 31,460 pregnancies undergoing first-trimester 317 
combined screening for aneuploidies without CVS and identified risk factors for 318 
miscarriage.13 They then applied this model in 2,396 pregnancies with CVS and 319 
found that the estimated number of miscarriages was 45 (95% CI 32 to 58) which 320 
was similar to the observed number of 44.13 Two subsequent studies following a 321 
similar methodology did not find significant differences between groups.14,15  322 
Second, a large national registry-based study assessing 147,987 singleton 323 
pregnancies that had first-trimester combined screening for aneuploidies, including 324 
5,072 that had CVS, reported that the average effect of CVS on risk of miscarriage 325 
was -0.21% (95% CI, -0.58 to 0.15).16 In this study the CVS-related risk of 326 
miscarriage was assessed by a dynamic PS stratification approach.16 The 327 
advantage of this approach is that it allows use of the whole sample but the major 328 





difference in baseline characteristics of the patients even within the same stratum. 330 
In our matching approach we used a 1:1 ratio and a small difference in PS between 331 
matched cases (calliper of 0.1) to ensure that the CVS and non-CVS groups had a 332 
very similar risk-profile.  333 
Third, a recent RCT randomized women at high-risk of aneuploidies into cell-334 
free DNA testing (n = 1,015) or invasive testing, both amniocentesis or CVS (n = 335 
982), and found not significant differences in the risk of miscarriage between the two 336 
groups (0.8% vs. 0.8%, for a risk difference of −0.03% (1-sided 95%CI, −0.68% to 337 
; P = 0.47).25 338 
Clinical implications 339 
In those cases where there is a clear indication to perform prenatal genetic testing, 340 
we can reassure women that their risk of miscarriage mainly depends on the results 341 
from genetic diagnosis and the conditions that lead to it more than the procedure 342 
itself. However, in the absence of any major fetal defect or other additional risk 343 
factors for chromosomal abnormalities, we should report an individualized 344 
procedure-related risk based on women clinical characteristics. 345 
Strengths and limitations  346 
The main limitations of the study derive from its observational and retrospective 347 
nature with the immediate consequence of the heterogeneity between comparison 348 
groups (figure 2). Although we tried to mitigate these differences, we were able to 349 
balance only those maternal and pregnancy characteristics that had been recorded, 350 





Additionally, we could not assess the influence of technical factors or experience of 352 
operators since they are not routinely recorded in any of the participating centers; 353 
however, its influence in the risk of miscarriage is well studied26,27. Fetal karyotype 354 
was not available in most cases miscarrying spontaneously and therefore our 355 
assumption on increased rate of aneuploidies among them remains hypothetical. 356 
We chose to exclude aneuploidies and fetal defects from the analysis because these 357 
would overestimate the risk of miscarriage in the CVS group, since they are the 358 
cases most likely to miscarry. However, this exclusion inevitably leads to the 359 
opposite effect as shown in our results: underestimation of the procedure-related risk 360 
due to lack of knowledge about karyotype in most of the miscarriages in the non-361 
CVS group while the CVS sample is “clean” of aneuploidies.  362 
The main strength of our study relates to the large sample of both, CVS and non-363 
CVS cases, which were selected after matching women of both groups but with 364 
identical propensity of CVS. Since the matching was indirectly based on known risk-365 
factors for aneuploidies, we were able to perform subgroup analysis to demonstrate 366 
the interaction between the risk of aneuploidies and CVS by comparing patients with 367 
a very similar risk-profile.  368 
All invasive procedures were performed by the same technique and by fetal 369 
medicine experts or their trainees at the end of such training. This represents both 370 
an advantage, because this reduces the variability between operators, and a 371 
disadvantage, since the results might not be valid for different approaches and level 372 






The risk of miscarriage in women having a CVS is about 1% higher than in women 375 
without CVS, although this excess risk is not entirely due to the invasive procedure 376 
but to some extent to the demographic and pregnancy characteristics of the patient 377 
undergoing CVS. After adjusting for these risk factors and confining the analysis to 378 
low-risk pregnancies, CVS seems to increase the risk of miscarriage about three 379 
times above the patient’s background-risk. Although this is a substantial increase in 380 
relative terms, in pregnancies without risk factors, the risk of miscarriage after CVS 381 
will remain low and similar to or slightly higher than that of the general population. 382 
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Table 1. Maternal and pregnancy characteristics of the study population.  512 
Data are given as median (interquartile range) or n (%). *The subset of women included in the 513 
propensity score regression analysis was taken from this group. hCG = human chorionic 514 
gonadotropin; PAPP-A = pregnancy associated plasma protein-A; Comparisons between outcome 515 
groups were by χ2-test for categoric variables and Mann-Whitney U test for continuous variables.  516 
Variable 
Non-chorionic 
villus sampling*  
(n = 22,250) 
Chorionic villus 
sampling 




Maternal age, y 32.5 (28.4, 35.8) 35.2 (31.4, 38.3) <0.0001 49.0 
Maternal weight, kg 64.0 (57.3, 73.0) 63.5 (57.0, 72.0) 0.0014 -5.4 
Maternal height, cm 163 (160, 168) 163 (159, 167) 0.0281 -3.4 
Racial origin    6.0 
White 21937 (98.6) 3526 (97.6) <0.0001  
Black 221 (1.0) 52 (1.4) 0.0190  
South Asian 21 (0.1) 13 (0.4) 0.0001  
East Asian 71 (0.3) 22 (0.6) 0.0108  
Method of conception   0.0048 4.9 
Natural 21258 (95.5) 3413 (94.5)   
Assisted 992 (4.5) 200 (5.5)   
Parity    18.0 
Nulliparous 10246 (46.0) 1345 (37.2) <0.0001  
Parous 12004 (54.0) 2268 (62.8) <0.0001  
Cigarette smoking 3137 (14.1) 467 (12.9) 0.0625 3.4 
Medical history     
Diabetes mellitus 223 (1.0) 40 (1.1) 0.4240 1.7 
Not known 1846 (8.3) 469 (13.0) <0.0001  
Chronic hypertension 157 (0.7) 46 (1.3) <0.0001 7.4 
Not known 66 (0.3) 510 (14.1) <0.0001  
Gestational age, wk 12.6 (12.2, 13.1) 13.0 (12.5, 13.5) <0.0001 50.4 
Delta nuchal translucency, mm 0.16 (-0.06, 0.40) 0.32 (‘-0.01, 0.85) <0.0001 43.4 
Ductus venosus      
Abnormal flow 1059 (4.8) 384 (10.6) <0.0001 26.6 
Not known 907 (4.1) 511 (14.1) <0.0001  
Free β-hCG, MoM 1.05 (0.69, 1.63) 1.29 (0.77, 2.12) <0.0001 28.9 
PAPP-A, MoM 0.94 (0.67, 1.34) 0.52 (0.32, 0.86) <0.0001 -69.1 





Table 2. Maternal and pregnancy characteristics of the chorionic villus sampling and non-517 
chorionic villus sampling cases matched by propensity score. 518 
Variable 
Non-chorionic 
villus sampling  
(n = 2,122) 
Chorionic villus 
sampling 




Maternal age, y 34.8 (31.5,37.7) 34.7 (31.1,37.9) 0.5789 2.1 
Maternal weight, kg 63.0 (57.0,71.5) 63.0 (56.6,71.2) 0.9949  -0.2 
Maternal height, cm 163 (159,167) 163 (159,167) 0.9582  -0.8 
Racial origin, n (%)   0.8592 1.1 
White 2107 (99.3) 2105 (99.2)   
Non-White 15 (0.7) 17 (0.8)   
Method of conception, n (%)   0.3681 3.0 
Natural 2019 (95.1) 2005 (94.5)   
Assisted 103 (4.9) 117 (5.5)   
Parity, n (%)   1.000 0.1 
Nulliparous 853 (40.2) 854 (40.2)   
Parous 1269 (59.8) 1268 (59.8)   
Cigarette smokers, n (%) 288 (13.6) 272 (12.8) 0.4963 -2.2 
Medical history, n (%)     
Diabetes mellitus (n= 2367; 2450) 20 (0.9) 23 (1.1) 0.8669 1.0 
Chronic hypertension 27 (1.3) 26 (1.2) 1.000 -0.4 
Gestational age, weeks 13.0 (12.5,13.4) 12.9 (12.4,13.4) 0.0414  -7.3 
Delta nuchal translucency, mm 0.33 (0.08,0.65) 0.26 (-0.02,0.65) <0.0001  0.3 
Abnormal flow in ductus venosus  251 (11.8) 232 (10.9) 0.3843 -2.8 
Free β-hCG, MoM 1.19 (0.74,1.91) 1.22 (0.75,1.96) 0.5273 6.3 
PAPP-A, MoM 0.66 (0.48,0.90) 0.52 (0.32,0.87) <0.0001  -9,9 
Miscarriage, n (%) 55 (2.6) 40 (1.9) 0.1463  
Data are given as median (interquartile range) or n (%). Comparisons between outcome groups were 519 
by chi, square test for categoric variables and Mann, Whitney U test for continuous variables.  520 
The covariates used to identify matched women without chorionic villus sampling were maternal age, 521 
weight height and racial origin, method of conception, parity, smoking status, chronic hypertension, 522 
gestational age, nuchal translucency, free β-hCG and PAPP-A. 523 






Figure legends 526 
 527 
Figure 1. Flow diagram of patients included in the study. CVS, chorionic villus 528 
sampling. 529 
 530 
Figure 2. Propensity score matching of cases with chorionic villus sampling with 531 
cases without chorionic villus sampling. The grey band denotes 10% standardised 532 
difference between covariates.  533 
 534 
Figure 3. Odds ratio for miscarriage after chorionic villus sampling in women with 535 
high and low risk of having a CVS. CVS, chorionic villus sampling. 536 
